Hemostemix Execs Attend 2026 Abundance360 Summit

Regenerative treatment ACP-01 takes center stage at biotech and longevity event.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Hemostemix Inc., a regenerative medicine company, announced that its CEO Thomas Smeenk and Chairman Peter Lacey are attending the 2026 Abundance360 Summit in Los Angeles this week. At the event, they will discuss the commercialization opportunities for Hemostemix's lead product, ACP-01 (VesCell), a regenerative treatment designed to increase health span by improving microvascular circulation and driving the growth of new blood vessels.

Why it matters

The Abundance360 Summit convenes leading entrepreneurs and investors working on cutting-edge biotechnology, artificial intelligence, and longevity science. Hemostemix's attendance highlights the potential of its regenerative therapy ACP-01 to address major health issues like cardiovascular disease, which is a key focus area for the longevity community.

The details

ACP-01 has been the subject of 11 peer-reviewed publications studying its effects on conditions including angina, ischemic cardiomyopathy, dilated cardiomyopathy, and chronic limb-threatening ischemia. Hemostemix has completed seven clinical studies involving 318 subjects and is now focused on commercializing ACP-01 in Florida and The Bahamas.

  • Hemostemix is attending the 2026 Abundance360 Summit in Los Angeles this week (March 9-12, 2026).
  • Hemostemix has completed seven clinical studies of ACP-01 involving 318 subjects.

The players

Thomas Smeenk

President and CEO of Hemostemix.

Peter Lacey

Chairman of Hemostemix.

Peter H. Diamandis

Founder of the Abundance360 Summit and a futurist and entrepreneur.

Hemostemix Inc.

A regenerative medicine company that has developed the autologous stem cell therapy ACP-01 (VesCell).

Got photos? Submit your photos here. ›

What they’re saying

“Abundance360 is an incredible event. 76% and 15% of Fountain Life members were found to have stage 1, or stage 2-3 coronary artery disease, respectively, after going trough the Fountain Life examinations. Peter Diamandis' motto 'do not die from something stupid' is obvious. The conversations about commercialization in Florida and The Bahamas are generating significant interest, as it is based on 498 treatments, seven clinical trials, and statistically significant improvement in heart function and circulation, which is the key to longevity.”

— Thomas Smeenk, President and CEO of Hemostemix (Newsfile Corp.)

What’s next

Hemostemix plans to continue discussions with investors and longevity participants at the Abundance360 Summit about the opportunity to join the company as shareholders in its commercialization stage in Florida and The Bahamas.

The takeaway

Hemostemix's regenerative therapy ACP-01 is generating significant interest in the longevity and biotechnology community, as it has shown promise in improving cardiovascular health and circulation - key factors in healthy aging. The company's attendance at the prestigious Abundance360 Summit highlights the potential of its technology to reshape the future of human health.